Summary:
A Randomized, Double-Blind, Double Dummy, Parallel Group, Multicenter 24 to 52 Week Variable Length Study to improve lung fuction with a single inhaler/ To assess the Efficacy and Safety of Budesonide, Glycopyrronium, and Formoterol Fumarate Metered Dose Inhaler (MDI) Relative to Budesonide and Formoterol Fumarate MDI and Symbicort® Pressurized MDI in Adult and Adolescent Participants with inadequate controlled asthma.
Criteria:• Age:12-80
• Diagnosed with persistent Asthma for at least 12 weeks
• Must be using stable daily medication for the treatment of persistent Asthma
• Must have a documented history of at least one Asthma exacerbation (asthma attack) requiring systemic corticosteroids (prednisone) associated with a doctor visit, hospitalization or ER visit due to your Asthma
• Can not have any other breathing condition or issue like COPD or Chronic Bronchitis
Qualified Participants May Receive:
- Study related exams and texts provided at no cost
- Study Asthma Medication provided at no cost
- Compensation of $75 per visit with up to 15 visits during screening and treatment
- Transportation may be provided to patients that qualify